- Home
- CELC vs CURV Comparison
CELC vs CURV Comparison
Compare CELC & CURV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- CURV
- Stock Information
- Founded
- CELC 2011
- CURV 2001
- Country
- CELC United States
- CURV United States
- Employees
- CELC N/A
- CURV N/A
- Industry
- CELC Medical Specialities
- CURV Clothing/Shoe/Accessory Stores
- Sector
- CELC Health Care
- CURV Consumer Discretionary
- Exchange
- CELC Nasdaq
- CURV Nasdaq
- Market Cap
- CELC 489.7M
- CURV 402.0M
- IPO Year
- CELC 2017
- CURV 2021
- Fundamental
- Price
- CELC $10.93
- CURV $6.29
- Analyst Decision
- CELC Strong Buy
- CURV Hold
- Analyst Count
- CELC 6
- CURV 5
- Target Price
- CELC $29.17
- CURV $5.25
- AVG Volume (30 Days)
- CELC 356.6K
- CURV 424.5K
- Earning Date
- CELC 11-14-2024
- CURV 12-03-2024
- Dividend Yield
- CELC N/A
- CURV N/A
- EPS Growth
- CELC N/A
- CURV 29.45
- EPS
- CELC N/A
- CURV 0.14
- Revenue
- CELC N/A
- CURV $1,121,714,000.00
- Revenue This Year
- CELC N/A
- CURV N/A
- Revenue Next Year
- CELC N/A
- CURV N/A
- P/E Ratio
- CELC N/A
- CURV $44.47
- Revenue Growth
- CELC N/A
- CURV N/A
- 52 Week Low
- CELC $10.35
- CURV $2.18
- 52 Week High
- CELC $22.19
- CURV $9.14
- Technical
- Relative Strength Index (RSI)
- CELC 35.65
- CURV 76.08
- Support Level
- CELC $10.35
- CURV $5.46
- Resistance Level
- CELC $13.80
- CURV $6.00
- Average True Range (ATR)
- CELC 0.83
- CURV 0.37
- MACD
- CELC -0.19
- CURV 0.04
- Stochastic Oscillator
- CELC 16.20
- CURV 100.00
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America targeting 27 to 42-year-old women. It is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of e-Commerce platform and stores.